Lifeworks Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.74M Sell
1,897
-175
-8% -$177K 0.22% 95
2025
Q4
$2.23M Sell
2,072
-334
-14% -$319K 0.29% 86
2025
Q3
$1.84M Sell
2,406
-6,815
-74% -$5.07M 0.24% 92
2025
Q2
$7.19M Sell
9,221
-291
-3% -$226K 1.07% 21
2025
Q1
$7.86M Buy
9,512
+1,358
+17% +$1.13M 1.31% 17
2024
Q4
$6.29M Buy
8,154
+975
+14% +$807K 1.14% 20
2024
Q3
$6.36M Sell
7,179
-301
-4% -$271K 1.25% 19
2024
Q2
$6.77M Buy
7,480
+179
+2% +$143K 1.89% 10
2024
Q1
$5.68M Buy
7,301
+361
+5% +$257K 1.59% 14
2023
Q4
$4.05M Sell
6,940
-1,195
-15% -$698K 1.4% 18
2023
Q3
$4.37M Sell
8,135
-1,866
-19% -$962K 1.7% 12
2023
Q2
$4.69M Buy
10,001
+67
+0.7% +$28.1K 2% 11
2023
Q1
$3.41M Buy
9,934
+71
+0.7% +$23.9K 1.61% 15
2022
Q4
$3.61M Buy
9,863
+346
+4% +$123K 2.03% 12
2022
Q3
$3.45M Sell
9,517
-333
-3% -$106K 1.96% 14
2022
Q2
$3.19M Sell
9,850
-633
-6% -$190K 2.02% 10
2022
Q1
$3M Buy
10,483
+5,023
+92% +$1.29M 1.98% 10
2021
Q4
$1.51M Buy
+5,460
New +$1.38M 1.2% 24

Other funds holding LLY

Lifeworks Advisors's LLY Position: Q1 2026 in Review

Lifeworks Advisors reduced its Eli Lilly (LLY) stake by 8.4% in Q1 2026, selling an estimated $177K and leaving 1,897 shares worth $1.74M. The position accounts for 0.22% of the portfolio, ranked #95.

Lifeworks Advisors first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $7.86M in Q1 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Lifeworks Advisors held 1,897 shares of Eli Lilly worth $1.74M as of Q1 2026.
  • Lifeworks Advisors sold 175 Eli Lilly shares in Q1 2026, an estimated $177K.
  • Eli Lilly made up 0.22% of Lifeworks Advisors's portfolio in Q1 2026, its #95 holding.
  • Lifeworks Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Lifeworks Advisors's Eli Lilly position peaked at $7.86M in Q1 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Lifeworks Advisors's 13F filing for Q1 2026, filed 4 May 2026.